1. medical condition: * known hypersensitivity to monoclonal antibody (mab) or investigational product (ip) component. * acute illness including fever on the day prior to or day of dosing. * any other significant disease increase the risk to participant study. 2. laboratory related: * aspartate aminotransferase (ast) or alanine aminotransferase (alt) \> 2.0 × upper limit of normal (uln), alkaline phosphatase (alp) \> 1.5 × uln, or tbl (total bilirubin) \> 1.5 × uln (unless due to gilbert's syndrome). * serum creatinine \> 176 μmol/l. * haemoglobin \< 10g/dl. * platelet count \< 100 × 10\^3/μl. * white blood cell count \< 3.5 × 10\^3/μl or neutrophil count \< 1.5 × 10\^3/μl. * other laboratory significantly abnormal in the screening panel that, in the opinion of the investigator, will increase participants risk or might confound analysis of study results. 3. covid-19 infection history/any receipt of mab indicated for covid-19. 4. prior/concomitant treatment: receipt of any investigational product within 90 days or 5 antibody half-lives (whichever is longer) prior to day 1

1. medical condition: * known hypersensitivity to monoclonal antibody (mab) or investigational product (ip) component. * acute illness including fever on the day prior to or day of dosing. * any other significant disease increase the risk to participant study. 2. laboratory related: * aspartate aminotransferase (ast) or alanine aminotransferase (alt) \> 2.0 × upper limit of normal (uln), alkaline phosphatase (alp) \> 1.5 × uln, or tbl (total bilirubin) \> 1.5 × uln (unless due to gilbert's syndrome). * serum creatinine \> 176 μmol/l. * haemoglobin \< 10g/dl. * platelet count \< 100 × 10\^3/μl. * white blood cell count \< 3.5 × 10\^3/μl or neutrophil count \< 1.5 × 10\^3/μl. * other laboratory significantly abnormal in the screening panel that, in the opinion of the investigator, will increase participants risk or might confound analysis of study results. 3. covid-19 infection history/any receipt of mab indicated for covid-19. 4. prior/concomitant treatment: receipt of any investigational product within 90 days or 5 antibody half-lives (whichever is longer) prior to day 1

medical condition: known hypersensitivity to monoclonal antibody (mab) or investigational product (ip) component. acute illness including fever on the day prior to or day of dosing. any other significant disease increase the risk to participant study. laboratory related: aspartate aminotransferase (ast) or alanine aminotransferase (alt) > 2.0 × upper limit of normal (uln), alkaline phosphatase (alp) > 1.5 × uln, or tbl (total bilirubin) > 1.5 × uln (unless due to gilbert's syndrome). serum creatinine > 176 μmol/l. haemoglobin < 10g/dl. platelet count < 100 × 10^3/μl. white blood cell count < 3.5 × 10^3/μl or neutrophil count < 1.5 × 10^3/μl. other laboratory significantly abnormal in the screening panel that, in the opinion of the investigator, will increase participants risk or might confound analysis of study results. covid-19 infection history/any receipt of mab indicated for covid-19. prior/concomitant treatment: receipt of any investigational product within 90 days or 5 antibody half-lives (whichever is longer) prior to day 1

medical condition: known hypersensitivity to monoclonal antibody (mab) or investigational product (ip) component. acute illness including fever on the day prior to or day of dosing. any other significant disease increase the risk to participant study. laboratory related: aspartate aminotransferase (ast) or alanine aminotransferase (alt) > 2.0 × upper limit of normal (uln), alkaline phosphatase (alp) > 1.5 × uln, or tbl (total bilirubin) > 1.5 × uln (unless due to gilbert's syndrome). serum creatinine > 176 μmol/l. haemoglobin < 10g/dl. platelet count < 100 × 10^3/μl. white blood cell count < 3.5 × 10^3/μl or neutrophil count < 1.5 × 10^3/μl. other laboratory significantly abnormal in the screening panel that, in the opinion of the investigator, will increase participants risk or might confound analysis of study results. covid-19 infection history/any receipt of mab indicated for covid-19. prior/concomitant treatment: receipt of any investigational product within 90 days or 5 antibody half-lives (whichever is longer) prior to day 1